mutations, both spontaneously and particularly after treatment with genotoxic agents. We also present evidence that the strength of the mutator phenotype is related to the expression level of the fusion protein. As with all types of AML, relapse is a major cause of mortality in t(8;21) AML. If remission-induction chemotherapy fails to eliminate all the RUNX1/ETO-positive cells, our data suggest that surviving cells are predisposed to mutations that could drive relapse. One consideration for chemotherapy should therefore be to limit mutation of surviving leukemic/preleukemic cells. As such, we hypothesise that targeting the mutator phenotype associated with expression of the RUNX1/ETO fusion gene could impede the acquisition of co-operating mutations required for disease relapse. Our data demonstrate the need to develop novel therapeutic strategies that avoid increasing the mutation burden of AML cells.
The treatment of CML was greatly improved with the introduction of tyrosine kinase inhibitors more than a decade ago, but not all patients respond optimally to the initial treatment and even after obtaining a deep molecular remission, discontinuation of treatment is often followed by a relapse. [3] [4] [5] The leukemic stem cell (LSC) burden of CML patients at diagnosis could potentially provide an important disease variable for predicting response to tyrosine kinase inhibitor (TKI) treatment. We previously estimated the LSC burden at the diagnosis of CML by quantification of primitive CD34 + CD38 low BCR/ABL1-positive cells, which was predictive of response to TKI therapy. 6 However, this procedure would be challenging to implement clinically, because it requires both sorting of CD34 + CD38 low CML cells and fluorescent in situ hybridization (FISH) analysis to enumerate BCR/ ABL1-positive cells. Here, we aimed at establishing a flow cytometry-based protocol to estimate the LSC burden at diagnosis by exploring the expression of cell surface markers reported to be upregulated on primitive CML CD34 10 and ST2 (IL1RL1 or IL33R). 11 Of these markers, only CD26 and IL1RAP, a co-receptor of the interleukin 1 receptor (IL1R1) with unknown function in normal and malignant hematopoiesis, have so far been proven to separate BCR/ABL1-positive from negative cells within the CD34 + CD38 low fraction. 7, 8 Here, we first used a staining protocol to simultaneously analyze the expression of these seven markers in bone marrow aspirates from five CML patients and two normal bone marrows. The LSC-containing CML CD34 + CD38 low compartment was defined as shown in Figure 1a . We found that IL1RAP, CD25 and CD26 were distinctly upregulated on primitive CML cells relative to corresponding cells in normal bone marrows, whereas the other markers showed a variable expression pattern or were expressed also on CD34 + CD38 low normal bone marrows cells (Figure 1b and Supplementary Table 1 ). CD123, CD117 and IL1R1 were all expressed on the immature CML CD34 + CD38 low cells but showed expression also on the normal hematopoietic stem cell. In contrast to a recent study reporting low ST2 expression on CML CD34 + CD38 low cells, 11 this marker could only be detected in one of five CML patients using the same antibody, possibly because of a lower sensitivity of our flow cytometry protocol. Thus IL1RAP, CD25 and CD26 were specifically expressed on CML CD34 + CD38 low cells compared with corresponding normal cells.
To study the expression of LSC markers in more detail, IL1RAP, CD25 and CD123 were chosen for further analysis using an optimized panel of antibodies. As CD25 and CD26 displayed similar expression patterns in primitive CML cells (Figure 1c) , consistent with previous studies, 8 we included only CD25 in the staining protocol. Instead we selected CD123 since antibodies targeting this receptor currently are being evaluated as a therapy in CML. 9 These three markers were analyzed in a cohort of 21 CML patients included in the NordCML006 study, in which patients were randomized to receive treatment either with imatinib or dasatinib. 12 A summary of patient data is provided in Supplementary Table 2 . Using the optimized protocol, we obtained a clear separation of both IL1RAP-positive and CD25-positive cells within the CML CD34 + CD38 low compartment, whereas CD123 expression failed to divide cells into distinct positive and negative cell populations (Figure 2a) . In normal bone marrows, we did not observe expression of IL1RAP or CD25 in the CD34 + CD38 low population, while CD123 was weakly expressed (Supplementary Figure 1) . While analyzing co-expression of IL1RAP and CD25 in the CML CD34 + CD38 low compartment, we found one population co-expressing IL1RAP and CD25 and one expressing only IL1RAP. No cells were found to express only CD25 (Figure 2b ). Although the cell fractions expressing IL1RAP and CD25 showed a significant correlation (r = 0.8558, P o 0.0001), IL1RAP was present on a consistently larger fraction of CML CD34 + CD38
low cells (mean of difference 25.62%, confidence interval 95% 15.81-35.44, P o0.0001).
To further delineate the difference between cells expressing IL1RAP and CD25, we correlated the flow cytometry data on IL1RAP and CD25 expression from the current study to previously reported BCR/ABL1 FISH data on the CML CD34 low BCR/ABL1-positive cells often lack CD25 expression (Figure 2d) . We then used a previously described Flow-FISH sorting technique to sort CD34 + CD38
low cells according to CD25 expression and evaluated the fraction BCR/ABL1-positive cells in four CML patients. We found that of the CD25 expressing cells, a mean of 98% were BCR/ABL1-positive cells (ranging between 94 and 100%), whereas the CD25-negative population of the same patients still contained a mean of 85% BCR/ABL1-positive cells (range between 46 and 99%). Consistent with our previous findings, 7 sorted IL1RAP-positive CD34 + CD38 low cells contained a great majority (99%) of BCR/ABL1-positive cells (Supplementary Figure 2) , whereas IL1RAP-negative cells were almost all BCR/ABL1-negative (5%). Taken together, these data show that IL1RAP is a marker for BCR/ABL1-positive cells in the CML CD34 + CD38 low fraction, whereas CD25 is only expressed on a subfraction of BCR/ABL1-positive cells.
The response of CML to TKI treatment is currently monitored by cytogenetic analyses and real-time quantitative reverse PCR analysis of BCR/ABL1 transcript levels. 4 However, so far no easily implementable laboratory-based method is available to estimate the LSC burden at diagnosis as a possible predictor of treatment response. We therefore investigated whether IL1RAP or CD25 expression in the CML CD34 + CD38 low compartment, as a measure of the LSC burden at diagnosis, could provide clinically relevant prognostic information. In our previous study, the presence of ⩾ 80% BCR/ABL1-positive cells by FISH in the CD34 + CD38 low fraction at diagnosis of CML was used to define a group of patients with 'high' LSC burden, whereas o80% were designated as 'low' LSC burden. 6 Based on IL1RAP expression, we used a similar definition, that is, patients were classified as IL1RAP low (n = 13, defined as o80% of the CD34 + CD38 low cells expressing IL1RAP) or IL1RAP high (n = 8, ⩾ 80% of CD34 + CD38 low cells expressing IL1RAP). Following this subdivision, we investigated if the two groups differed in the probability of achieving optimal response as defined by the European Leukemia Net guidelines, following TKI treatment (Supplementary Table 3) . 4 All IL1RAP low and 7 of 8 IL1RAP high patients achieved BCR/ABL1 transcript levels ⩽ 10% within 3 months. However, IL1RAP low patients had a higher chance of reaching transcript levels o1% after 6 months (P = 0.0475), a definition of optimal response according to European Leukemia Net. 4 Since this cohort consisted of mainly optimal responders at 3 months, we looked at even deeper levels of molecular and cytogenetic response, previously shown to predict long-term outcome at this time point. 13, 14 Interestingly, IL1RAP low patients (13 out of a total of 21) had a higher chance of achieving complete cytogenetic response (P = 0.0009) and major molecular response (BCR/ABL1 transcript levels ⩽ 0.1%) after 3 months (P = 0.023) (Supplementary Table 3 ). No significant correlations were seen between IL1RAP expression and Sokal or Hasford risk scores. Altogether, this suggests that IL1RAP expression as a measure of LSC burden at diagnosis predicts cytogenetic and molecular response to TKI treatment although larger prospective studies are needed before such measurement can be implemented clinically.
Previously, light scattering properties together with CD34 and CD45 expression have been shown to differentiate between BCR/ABL1-positive and -negative CML CD34 + CD38 low cells. 15 Using that protocol, it was shown that the LSC burden at diagnosis could predict the complete cytogenetic response after 1 year of treatment as well as major molecular response after 1.5 years. No correlations were made to response after 3 months of therapy. Other investigators have used CD26 as a marker for primitive CML cells and showed a correlation with leukocyte counts at diagnosis but not with Sokal or Hasford risk scores, possible association with cytogenetic and molecular response were not reported. 8 In contrast to our results, the authors could not detect overexpression of IL1RAP on primitive CML cells in all patients. Most likely, the difference in the two studies is a result of different sensitivities of the two assays to detect IL1RAP expression. All patients in our study clearly expressed IL1RAP; even in a patient in which FISH analysis of sorted CD34 + CD38 low cells revealed o1% BCR/ABL1-positive cells, a fraction of cells expressed IL1RAP (patient no. 10, Supplementary Table 2 ).
In conclusion, we identified IL1RAP, CD25 and CD26 as the most specific markers for primitive CML cells relative to the corresponding normal cells and demonstrate that the percentage of IL1RAP expressing cells within the CD34 low compartment in five CML patients, isotype control (red) and staining antibody (blue).
used to predict the response to TKI treatment. The described flow cytometry-based protocol may become a valuable prognostic tool in the management of CML patients. 
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